ESSA Pharma, Inc.
(TSX Venture Exchange : EPIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
1.16%142.080.7%$1093.09m
PFEPfizer Inc.
0.52%43.720.9%$890.78m
MRKMerck & Co., Inc.
-0.82%84.660.6%$748.07m
BMYBristol-Myers Squibb Company
0.76%48.981.4%$532.91m
LLYEli Lilly and Company
0.50%115.811.0%$486.16m
ABBVAbbVie, Inc.
1.21%78.552.2%$356.10m
NVSNovartis AG Sponsored ADR
0.51%92.380.2%$198.97m
AZNAstraZeneca PLC Sponsored ADR
0.12%41.731.2%$117.53m
GSKGlaxoSmithKline plc Sponsored ADR
-1.03%40.580.2%$89.06m
SNYSanofi Sponsored ADR
-0.17%44.010.2%$87.02m
NVONovo Nordisk A/S Sponsored ADR Class B
-2.67%51.020.1%$76.88m
LCILannett Company, Inc.
-0.18%5.6736.6%$4.59m
AKTXAkari Therapeutics Plc Sponsored ADR
-3.72%2.111.6%$0.43m
EPIXESSA Pharma Inc
3.27%2.380.1%$0.01m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.